Pfizer 2Q Revenues: $13.5 billion (+4%) 2Q Earnings: $3.9 billion (+20%) YTD Revenues: $26.4 billion (+3%) YTD Earnings: $7.4 billion (20%) Comments: Innovative Health sales were $8.3 billion in the quarter, up 8%. Growth from key brands included Eliquis, Ibrance and Xeljanz globally, Prevnar 13/Prevenar 13 primarily in emerging markets and the U.S., as well as Xtandi in the U.S. Operational revenue growth for Eliquis, Ibrance, Xeljanz and Xtandi was 42%, 19%, 37% and 21%, respectively. Ess...